ABBV - AbbVie Inc. Последние новости | Finranks

12.10.2026

AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie continues to diversify its portfolio through the successful expansion of newer therapies like Skyrizi and Rinvoq. Eli Lilly and has seen explosive growth driven by its dominant presence in the massive cardiometabolic treatment market.

12.10.2026

AbbVie (ABBV) Rises As Market Takes a Dip: Key Facts

AbbVie (ABBV) reached $281.04 at the closing of the latest trading day, reflecting a +1.65% change compared to its last close.

12.10.2026

Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism

Biotechnology stocks are showing signs of a renewed recovery, supported by a pickup in pharmaceutical mergers and acquisitions and investor interest in drug development pipelines. Key Takeaways: Big pharma acquisitions are hitting record highs to combat impending patent cliffs.

12.10.2026

Will Skyrizi & Rinvoq Drive AbbVie's Top-Line Growth in Q3?

ABBV's Skyrizi and Rinvoq are expected to drive Q3 growth, offset Humira's ongoing decline and face rising competition in the immunology market.

12.10.2026

Prediction: AbbVie's Next Billion-Dollar Opportunity Is Taking Shape

Skyrizi and Rinvoq are growing fast, a blockbuster acquisition just closed, and the FDA handed AbbVie a fresh approval, yet the stock sits just shy of a price target that has Wall Street divided between a $297 bull case and

11.10.2026

New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease

New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints and observed subgroups New open-label extension analyses demonstrate sustained endoscopic outcomes over time with SKYRIZI, even in patients with complex disease characteristics and prior treatment exposure In real-world studies, patients with advanced Crohn's disease achieved disease control with RINVOQ, highlighting its potential benefit for difficult-to-treat patients The breadth of scientific abstracts and oral presentations at the American College of Gastroenterology 2026 Annual Scientific Meeting demonstrates AbbVie's pursuit to address the complexities of inflammatory bowel disease care NORTH CHICAGO, Ill., Oct. 11, 2026 /PRNewswire/ -- AbbVie today announced the presentation of 22 scientific abstracts from its market-leading inflammatory bowel disease (IBD) portfolio at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting in Nashville, Tennessee, Oct. 9-14.

11.10.2026

5 Dividend Stocks for Retirees Who Want More Than Just a Big Yield

A 5% Treasury yield raises the bar for every dividend stock in a retirement portfolio, and not every high-yielder clears it.

Видео

24.08.2026

Positive

Emily Field: Large pharma companies are going to continue looking at biotech

14.08.2026

Positive

Expert explains why healthcare is a top-performing sector

Повышения / Понижения рейтинга

Тикер	Фирма	Изменение рейтинга	Целевая цена	Дата
ABBV	Wolfe Research	Outperform	undefined >> $300	August 13th 2026
ABBV	Erste Group	Buy	undefined >> undefined	August 5th 2026

Пресс-релизы

11.10.2026

AbbVie Inc. (ABBV)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Контакты

Мы в соцсетях

AbbVie Inc. (ABBV)

AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie (ABBV) Rises As Market Takes a Dip: Key Facts

Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism

Will Skyrizi & Rinvoq Drive AbbVie's Top-Line Growth in Q3?

Prediction: AbbVie's Next Billion-Dollar Opportunity Is Taking Shape

New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease